Access restrictions were established for this page. If you see this message, you have no access to this page.
سامان رنجبر (بحث | مشارکتها) |
سامان رنجبر (بحث | مشارکتها) |
||
| خط ۳۸: | خط ۳۸: | ||
High-dose benfotiamine (up to 600 mg/day) has been shown in short-term studies (3–12 weeks) to improve symptom scores in diabetic polyneuropathy<ref>[https://pubmed.ncbi.nlm.nih.gov/15726875 Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) ]</ref><ref>[ https://pubmed.ncbi.nlm.nih.gov/18473286 Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study ]</ref> | High-dose benfotiamine (up to 600 mg/day) has been shown in short-term studies (3–12 weeks) to improve symptom scores in diabetic polyneuropathy<ref>[https://pubmed.ncbi.nlm.nih.gov/15726875 Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) ]</ref><ref>[ https://pubmed.ncbi.nlm.nih.gov/18473286 Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study ]</ref> | ||
Benfotiamine blocks several hyperglycemia‐induced pathways of tissue damage in the retina and causes a reduction in superoxide production. | |||
<ref>[https://pubmed.ncbi.nlm.nih.gov/15726875 Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) ]</ref> | |||
Benfotiamine has direct antioxidant properties as well<ref>[https://pubmed.ncbi.nlm.nih.gov/18384109 Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro ]</ref>. | |||
It has been shown that treatment with benfotiamine avoids functional and structural changes in the retina. Benfotiamine has been demonstrated that benfotiamine protects against non-diabetic vascular damage<ref>[ https://pubmed.ncbi.nlm.nih.gov/20107192 Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway]</ref> | |||
In a recent study, benfotiamine was shown to prevent cardiac dysfunction in diabetes through modulating PI3 kinase‐AKT pathwayپ <ref>[https://pubmed.ncbi.nlm.nih.gov/20107192 Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway ]</ref> | In a recent study, benfotiamine was shown to prevent cardiac dysfunction in diabetes through modulating PI3 kinase‐AKT pathwayپ <ref>[https://pubmed.ncbi.nlm.nih.gov/20107192 Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway ]</ref> | ||
Therefore, by affecting oxidative stress, a common pathogenetic pathway, benfotiamine might potentially prevent multiple chronic diabetes problems <ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015539/ Preventive effects of benfotiamine in chronic diabetic complications ]</ref>. | Therefore, by affecting oxidative stress, a common pathogenetic pathway, benfotiamine might potentially prevent multiple chronic diabetes problems <ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015539/ Preventive effects of benfotiamine in chronic diabetic complications ]</ref>. | ||
Ramin Taghizadeh | Ramin Taghizadeh | ||